CSL (CSL.AX) Stock Price
CSL Price
CSL (CSL.AX) Stock | ISIN AU000000CSL8 | WKN 890952. The current CSL stock price is 72.93 USD (2026). Revenue is 16 B USD. Net income is 3.4 B USD. The P/E ratio is 10.42. Market capitalization is 35.46 B USD. CSL operates in the Health sector.
CSL stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of CSL over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CSL stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CSL's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | CSL Price |
|---|
CSL Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
CSL Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales CSL generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CSL retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CSL's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares CSL has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CSL's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
CSL stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
CSL Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
CSL business model & stock analysis
CSL SWOT Analysis
Strengths
CSL Ltd has a strong portfolio of life-saving products, including vaccines, gene therapies, and plasma-derived therapies. This diverse product range helps to mitigate risks and ensures a consistent revenue stream.
The company has a major competitive advantage through its strong research and development capabilities. It invests heavily in innovation and clinical trials, resulting in a continuous pipeline of new products and treatments.
Weaknesses
One of CSL Ltd's weaknesses lies in its geographical concentration of operations. With the majority of its manufacturing facilities located in Australia, the company is exposed to risks associated with regulatory changes, natural disasters, and disruptions in the supply chain.
Additionally, CSL Ltd heavily relies on plasma for its products. Any significant disruption in the plasma supply chain could impact production and lead to potential shortages.
Opportunities
The increasing demand for healthcare products and services globally provides CSL Ltd with significant growth opportunities. Expanding into emerging markets with a high demand for quality healthcare can help the company increase its market share and revenue.
The advancements in gene therapies and biotechnology open doors for CSL Ltd to develop new and innovative treatments. Partnering with academic institutions and biotechnology companies can enable the company to stay at the forefront of cutting-edge research.
Threats
CSL Ltd faces the threat of increasing competition from both established pharmaceutical companies and emerging biotech startups. This could potentially impact market share and profit margins.
The changing regulatory landscape, especially in the healthcare industry, also poses a threat to CSL Ltd. Compliance with evolving regulations and the possibility of stricter regulations can increase costs and limit operational flexibility.
CSL Eulerpool Fair Value
CSL historical P/E ratio, EBIT multiple, and P/S ratio
CSL annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
CSL shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
CSL Dividend History
33 years of dividend payments · 14 consecutive increases
CSL dividend history and estimates
Max
Details
CSL dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
CSL Earnings Estimates
CSL Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 2/12/2024 | 4.8USD | 8.2 BUSD | 2024 Q2 |
| 8/15/2023 | 1.93USD | 6.3 BUSD | 2023 Q4 |
| 2/14/2023 | 3.49USD | 7.05 BUSD | 2023 Q2 |
| 8/17/2022 | 1.1USD | 4.71 BUSD | 2022 Q4 |
| 2/16/2022 | 3.6USD | 6 BUSD | 2022 Q2 |
| 8/18/2021 | 1.06USD | 4.48 BUSD | 2021 Q4 |
| 2/18/2021 | 3.14USD | 5.7 BUSD | 2021 Q2 |
| 8/19/2020 | 1.95USD | 4.48 BUSD | 2020 Q4 |
| 2/12/2020 | 2.87USD | 4.9 BUSD | 2020 Q2 |
| 8/14/2019 | 1.71USD | 4.11 BUSD | 2019 Q4 |
EESG©
Eulerpool ESG Scorecard© for the CSL stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
CSL shareholder structure
| % | Name |
|---|---|
5.98682% | |
4.99162% | |
2.90077% | |
1.77796% | |
1.57518% | |
1.53251% | |
0.95152% | |
0.87712% | |
0.75144% | |
0.71872% |
CSL Executives and Management Board
Mr. Paul Mckenzie
(58)Chief Executive Officer, Managing Director, Executive Director · since 2019
Ms. Joy Linton
(58)Chief Financial Officer
Mr. Greg Boss
(62)Executive Vice President, Legal and CSL Group General Counsel
Dr. William Mezzanotte
(65)Executive Vice President, Head Research & Development
Dr. Brian Mcnamee
(67)Non-Executive Independent Chairman of the Board
CSL Supply Chain
Frequently asked questions about CSL
The business model of CSL Ltd is focused on providing innovative biotherapies and pharmaceutical products to patients worldwide. With a strong commitment to research and development, CSL specializes in developing plasma-derived and recombinant therapies for various medical conditions. The company's portfolio includes immunoglobulins, vaccines, and coagulation factors, among others. CSL operates through its two main business segments, CSL Behring and Seqirus. CSL Behring focuses on developing and manufacturing therapies for rare and serious diseases, while Seqirus is dedicated to producing influenza vaccines. CSL Ltd's business model emphasizes delivering high-quality and life-saving treatments to improve the health and well-being of individuals globally.
CSL stock
CSL Peer Group
CSL Ticker
CSL FIGI
All fundamentals and in-depth analysis of CSL
Our stock analysis for CSL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.